

NCI TABLE 1. LEO Patient Characteristics by Subtype - U01 CA195568-06 Progress Report (2/1/2022)
LEO Phase 1 Cases (consented 7/1/2015 to 5/31/2020)

	DLBCL (N=2559)	FL (N=1626)	MCL (N=766)	MZL (N=706)	TCL (N=688)	Other NHL (N=1230)	Composites (N=173)	Total (N=7748)
Age @ Diagnosis								
N	2559	1626	766	706	688	1230	173	7748
Mean (SD)	61.3 (14.9)	59.8 (12.9)	63.3 (10.2)	61.6 (13.6)	59.0 (15.3)	58.5 (16.2)	63.0 (14.4)	60.6 (14.3)
Median	63.0	60.0	63.0	63.0	60.5	61.0	64.0	62.0
Q1, Q3	53.0, 72.0	52.0, 69.0	57.0, 70.0	52.0, 71.0	49.0, 70.0	48.0, 71.0	55.0, 73.0	52.0, 71.0
Range	(18.0-99.0)	(18.0-94.0)	(31.0-98.0)	(19.0-94.0)	(18.0-91.0)	(18.0-97.0)	(21.0-91.0)	(18.0-99.0)
Gender								
Male	1464 (57.2%)	800 (49.2%)	590 (77.0%)	293 (41.5%)	416 (60.5%)	707 (57.5%)	90 (52.0%)	4360 (56.3%)
Female	1095 (42.8%)	826 (50.8%)	176 (23.0%)	413 (58.5%)	272 (39.5%)	523 (42.5%)	83 (48.0%)	3388 (43.7%)
Ethnicity								
Non-Hispanic/Latinx	2191 (85.6%)	1427 (87.8%)	684 (89.3%)	599 (84.8%)	597 (86.8%)	1085 (88.2%)	150 (86.7%)	6733 (86.9%)
Hispanic/Latinx	312 (12.2%)	161 (9.9%)	61 (8.0%)	93 (13.2%)	64 (9.3%)	112 (9.1%)	20 (11.6%)	823 (10.6%)
Unknown/Not reported	56 (2.2%)	38 (2.3%)	21 (2.7%)	14 (2.0%)	27 (3.9%)	33 (2.7%)	3 (1.7%)	192 (2.5%)
Race								
White	2174 (85.0%)	1457 (89.6%)	704 (91.9%)	614 (87.0%)	525 (76.3%)	1030 (83.7%)	154 (89.0%)	6658 (85.9%)
Black/AA	185 (7.2%)	59 (3.6%)	16 (2.1%)	53 (7.5%)	105 (15.3%)	112 (9.1%)	11 (6.4%)	541 (7.0%)
Native Hawaiian/PI	4 (0.2%)	4 (0.2%)	0 (0.0%)	1 (0.1%)	1 (0.1%)	2 (0.2%)	0 (0.0%)	12 (0.2%)
Asian	77 (3.0%)	33 (2.0%)	10 (1.3%)	13 (1.8%)	25 (3.6%)	33 (2.7%)	2 (1.2%)	193 (2.5%)
Am Indian/Alaska	4 (0.2%)	5 (0.3%)	7 (0.9%)	2 (0.3%)	5 (0.7%)	4 (0.3%)	0 (0.0%)	27 (0.3%)
>One Race	12 (0.5%)	6 (0.4%)	3 (0.4%)	4 (0.6%)	5 (0.7%)	12 (1.0%)	1 (0.6%)	43 (0.6%)
Unknown/Patient Unsure	103 (4.0%)	62 (3.8%)	26 (3.4%)	19 (2.7%)	22 (3.2%)	37 (3.0%)	5 (2.9%)	274 (3.5%)
Any Blood Biospecimens								
no	550 (21.5%)	368 (22.6%)	194 (25.3%)	189 (26.8%)	214 (31.1%)	310 (25.2%)	38 (22.0%)	1863 (24.0%)
yes	2099 (78.5%)	1258 (77.4%)	572 (74.7%)	517 (73.2%)	474 (68.9%)	920 (74.8%)	135 (78.0%)	5885 (76.0%)
Peripheral Blood DNA (extracted)								
no	658 (25.7%)	452 (27.8%)	224 (29.2%)	215 (30.5%)	232 (33.7%)	349 (28.4%)	45 (26.0%)	2175 (28.1%)
yes	1901 (74.3%)	1174 (72.2%)	542 (70.8%)	491 (69.5%)	456 (66.3%)	881 (71.6%)	128 (74.0%)	5573 (71.9%)
Buffy Coat (banked)								
no	1026 (40.1%)	750 (46.1%)	369 (48.2%)	299 (42.4%)	297 (43.2%)	449 (36.5%)	74 (42.8%)	3264 (42.1%)
yes	1533 (59.9%)	876 (53.9%)	397 (51.8%)	407 (57.6%)	391 (56.8%)	781 (63.5%)	99 (57.2%)	4484 (57.9%)

NCI TABLE 1. LEO Patient Characteristics by Subtype - U01 CA195568-06 Progress Report (2/1/2022)
LEO Phase 1 Cases (consented 7/1/2015 to 5/31/2020)

	DLBCL (N=2559)	FL (N=1626)	MCL (N=766)	MZL (N=706)	TCL (N=688)	Other NHL (N=1230)	Composites (N=173)	Total (N=7748)
Serum								
no	558 (21.8%)	373 (22.9%)	196 (25.6%)	190 (26.9%)	214 (31.1%)	314 (25.5%)	38 (22.0%)	1883 (24.3%)
yes	2001 (78.2%)	1253 (77.1%)	570 (74.4%)	516 (73.1%)	474 (68.9%)	916 (74.5%)	135 (78.0%)	5865 (75.7%)
Plasma								
no	553 (21.6%)	373 (22.9%)	196 (25.6%)	190 (26.9%)	215 (31.3%)	311 (25.3%)	38 (22.0%)	1876 (24.2%)
yes	2006 (78.4%)	1253 (77.1%)	570 (74.4%)	516 (73.1%)	473 (68.8%)	919 (74.7%)	135 (78.0%)	5872 (75.8%)
On Tissue Microarray								
no	2104 (82.2%)	1173 (72.1%)	626 (81.7%)	705 (99.9%)	557 (81.0%)	1230 (100.0%)	163 (94.2%)	6558 (84.6%)
yes	455 (17.8%)	453 (27.9%)	140 (18.3%)	1 (0.1%)	131 (19.0%)	0 (0.0%)	10 (5.8%)	1190 (15.4%)
Enroll Qx Completed								
no	760 (29.7%)	439 (27.0%)	243 (31.7%)	197 (27.9%)	219 (31.8%)	313 (25.4%)	48 (27.7%)	2219 (28.6%)
yes	1799 (70.3%)	1187 (73.0%)	523 (68.3%)	509 (72.1%)	469 (68.2%)	917 (74.6%)	125 (72.3%)	5529 (71.4%)
RFQ Completed								
no	1114 (43.5%)	660 (40.6%)	315 (41.1%)	294 (41.6%)	318 (46.2%)	495 (40.2%)	68 (39.3%)	3264 (42.1%)
yes	1445 (56.5%)	966 (59.4%)	451 (58.9%)	412 (58.4%)	370 (53.8%)	735 (59.8%)	105 (60.7%)	4484 (57.9%)
Any Follow-Up Qx Completed								
no	661 (25.8%)	307 (18.9%)	165 (21.5%)	141 (20.0%)	229 (33.3%)	290 (23.6%)	38 (22.0%)	1831 (23.6%)
yes	1898 (74.2%)	1319 (81.1%)	601 (78.5%)	565 (80.0%)	459 (66.7%)	940 (76.4%)	135 (78.0%)	5917 (76.4%)
Status								
Deceased	526 (20.6%)	95 (5.8%)	143 (18.7%)	48 (6.8%)	252 (36.6%)	213 (17.3%)	34 (19.7%)	1311 (16.9%)
Active follow-up	1890 (73.9%)	1429 (87.9%)	569 (74.3%)	612 (86.7%)	391 (56.8%)	933 (75.9%)	128 (74.0%)	5952 (76.8%)
Passive follow-up	107 (4.2%)	74 (4.6%)	42 (5.5%)	31 (4.4%)	30 (4.4%)	61 (5.0%)	9 (5.2%)	354 (4.6%)
Withdrawal, keep samples	17 (0.7%)	12 (0.7%)	3 (0.4%)	8 (1.1%)	3 (0.4%)	14 (1.1%)	2 (1.2%)	59 (0.8%)
Withdrawal, discard samples	4 (0.2%)	4 (0.2%)	1 (0.1%)	3 (0.4%)	3 (0.4%)	3 (0.2%)	0 (0.0%)	18 (0.2%)
Lost to Follow-up, no outside auth	15 (0.6%)	12 (0.7%)	8 (1.0%)	4 (0.6%)	9 (1.3%)	6 (0.5%)	0 (0.0%)	54 (0.7%)
Current Age for Alive Subjects								
N	2032	1530	623	658	436	1017	139	6435
Mean (SD)	64.2 (14.8)	64.1 (12.8)	67.2 (10.0)	65.3 (13.2)	61.7 (15.1)	61.7 (16.0)	66.9 (14.4)	64.1 (14.1)
Median	66.5	64.6	67.4	67.0	63.2	64.6	67.5	65.7
Q1, Q3	55.5, 75.0	55.9, 73.5	60.9, 73.9	56.4, 74.9	51.6, 73.3	51.8, 73.8	59.1, 77.2	55.8, 74.3
Range	(22.1-104.1)	(24.0-97.7)	(35.6-102.9)	(22.8-98.5)	(21.0-93.8)	(21.1-96.1)	(24.3-95.0)	(21.0-104.1)

NCI TABLE 1. LEO Patient Characteristics by Subtype - U01 CA195568-06 Progress Report (2/1/2022)
LEO Phase 1 Cases (consented 7/1/2015 to 5/31/2020)

	DLBCL (N=2559)	FL (N=1626)	MCL (N=766)	MZL (N=706)	TCL (N=688)	Other NHL (N=1230)	Composites (N=173)	Total (N=7748)
Primary COD								
(Alive)	2032 (79.4%)	1530 (94.1%)	623 (81.3%)	658 (93.2%)	436 (63.4%)	1017 (82.7%)	139 (80.3%)	6435 (83.1%)
Due to this Disease (i.e. progressive lymphoma)	255 (10.0%)	30 (1.8%)	55 (7.2%)	5 (0.7%)	143 (20.8%)	85 (6.9%)	14 (8.1%)	587 (7.6%)
Due to Therapy - Infection	43 (1.7%)	6 (0.4%)	7 (0.9%)	2 (0.3%)	20 (2.9%)	16 (1.3%)	5 (2.9%)	99 (1.3%)
Due to Therapy - Cardiac	13 (0.5%)	0 (0.0%)	3 (0.4%)	1 (0.1%)	1 (0.1%)	2 (0.2%)	1 (0.6%)	21 (0.3%)
Due to Therapy - Other	12 (0.5%)	3 (0.2%)	1 (0.1%)	0 (0.0%)	5 (0.7%)	3 (0.2%)	2 (1.2%)	26 (0.3%)
Due to a Secondary Malignancy	16 (0.6%)	11 (0.7%)	4 (0.5%)	4 (0.6%)	5 (0.7%)	8 (0.7%)	2 (1.2%)	50 (0.6%)
Due to Other Causes	66 (2.6%)	12 (0.7%)	15 (2.0%)	18 (2.5%)	19 (2.8%)	40 (3.3%)	4 (2.3%)	174 (2.2%)
Unable to Obtain Records	33 (1.3%)	10 (0.6%)	24 (3.1%)	4 (0.6%)	29 (4.2%)	21 (1.7%)	1 (0.6%)	122 (1.6%)
Deceased - Pending Physician Review	80 (3.1%)	22 (1.4%)	34 (4.4%)	13 (1.8%)	30 (4.4%)	36 (2.9%)	4 (2.3%)	219 (2.8%)
Deceased - No Physician Review	9 (0.4%)	2 (0.1%)	0 (0.0%)	1 (0.1%)	0 (0.0%)	2 (0.2%)	1 (0.6%)	15 (0.2%)
EFS Event								
Yes	731 (28.6%)	355 (21.8%)	247 (32.2%)	147 (20.8%)	355 (51.6%)	324 (26.3%)	59 (34.1%)	2218 (28.6%)
<i>EFS Component</i>								
Disease Progression/Relapse	414 (16.2%)	256 (15.7%)	163 (21.3%)	100 (14.2%)	228 (33.1%)	176 (14.3%)	28 (16.2%)	1365 (17.6%)
New Treatment	19 (0.7%)	10 (0.6%)	10 (1.3%)	4 (0.6%)	11 (1.6%)	8 (0.7%)	2 (1.2%)	64 (0.8%)
Transformation	12 (0.5%)	30 (1.8%)	2 (0.3%)	8 (1.1%)	3 (0.4%)	9 (0.7%)	9 (5.2%)	73 (0.9%)
Death	286 (11.2%)	59 (3.6%)	72 (9.4%)	35 (5.0%)	113 (16.4%)	131 (10.7%)	20 (11.6%)	716 (9.2%)
Second Primary Malignancy								
no	2452 (95.8%)	1551 (95.4%)	727 (94.9%)	673 (95.3%)	655 (95.2%)	1180 (95.9%)	161 (93.1%)	7399 (95.5%)
yes	107 (4.2%)	75 (4.6%)	39 (5.1%)	33 (4.7%)	33 (4.8%)	50 (4.1%)	12 (6.9%)	349 (4.5%)

(report generated on 24JAN2022)